{
    "eid": "2-s2.0-85133449449",
    "title": "Structural dynamics and kinase inhibitory activity of three generations of tyrosine kinase inhibitors against wild-type, L858R/T790M, and L858R/T790M/C797S forms of EGFR",
    "cover-date": "2022-08-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Computer Science Applications",
            "@code": "1706",
            "@abbrev": "COMP"
        },
        {
            "@_fa": "true",
            "$": "Health Informatics",
            "@code": "2718",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "Drug resistance",
        "EGFR inhibitor",
        "Kinase inhibition",
        "Molecular dynamics simulation"
    ],
    "authors": [
        "Duangjai Todsaporn",
        "Panupong Mahalapbutr",
        "Rungtiva P. Poo-arporn",
        "Kiattawee Choowongkomon",
        "Thanyada Rungrotmongkol"
    ],
    "citedby-count": 7,
    "ref-count": 105,
    "ref-list": [
        "Osimertinib making a breakthrough in lung cancer targeted therapy",
        "Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update",
        "Shikonin inhibits gefitinib-resistant non-small cell lung cancer by inhibiting TrxR and activating the EGFR proteasomal degradation pathway",
        "Targeting drug resistance in EGFR with covalent inhibitors: a structure-based design approach",
        "Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug\u2013drug interactions",
        "A comprehensive pathway map of epidermal growth factor receptor signaling",
        "Untangling the ErbB signalling network",
        "Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery",
        "Epidermal growth factor receptor-mediated cell motility: phospholipase C activity is required, but mitogen-activated protein kinase activity is not sufficient for induced cell movement",
        "A family of proteins that inhibit signalling through tyrosine kinase receptors",
        "A sequence motif in the transmembrane region of growth factor receptors with tyrosine kinase activity mediates dimerization",
        "Epidermal growth factor receptor (EGFR) signaling in cancer",
        "Global cancer statistics, 2012",
        "The role of adjuvant monoclonal antibody therapy for breast cancer: rationale and new studies",
        "Epidermal growth factor receptor protein expression and gene amplification in small cell carcinoma of the urinary bladder",
        "Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study",
        "Erlotinib in previously treated non\u2013small-cell lung cancer",
        "Cancer statistics, 2015",
        "Structure-based approach for the discovery of pyrrolo [3, 2-d] pyrimidine-based EGFR T790M/L858R mutant inhibitors",
        "Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths",
        "Determinants of tumor response and survival with erlotinib in patients with non\u2014small-cell lung cancer",
        "Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non\u2013small cell lung cancer: a randomized trial",
        "Discovery of (R)-1-(3-(4-amino-3-(3-chloro-4-(pyridin-2-ylmethoxy) phenyl)-1 H-pyrazolo [3, 4-d] pyrimidin-1-yl) piperidin-1-yl) prop-2-en-1-one (CHMFL-EGFR-202) as a novel irreversible EGFR mutant kinase inhibitor with a distinct binding mode",
        "Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial",
        "Treatment of non\u2013small-cell lung cancer with erlotinib or gefitinib",
        "Quantum mechanics/molecular mechanics modeling of covalent addition between EGFR\u2013cysteine 797 and N-(4-anilinoquinazolin-6-yl) acrylamide",
        "EGFR mutation and resistance of non\u2013small-cell lung cancer to gefitinib",
        "Precedence and Promise of Covalent Inhibitors of EGFR and KRAS for Patients with Non-small-cell Lung Cancer",
        "Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR pp 3482\u20133488",
        "Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation",
        "Characterization of irreversible kinase inhibitors by directly detecting covalent bond formation: a tool for dissecting kinase drug resistance",
        "Discovery of potent and noncovalent reversible EGFR kinase inhibitors of EGFRL858R/T790M/C797S",
        "PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib",
        "Novel mutant-selective EGFR kinase inhibitors against EGFR T790M",
        "Epidermal growth factor receptor (EGFR) signaling and covalent EGFR inhibition in lung cancer",
        "Drug discovery for a new generation of covalent drugs",
        "Drug\u2013target residence time and its implications for lead optimization",
        "Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib",
        "Phase IIb/III double-blind randomized trial of BIBW 2992, an irreversible, dual inhibitor of EGFR and HER2 plus best supportive care (BSC) versus placebo plus BSC in patients with NSCLC failing 1\u20132 lines of chemotherapy (CT) and erlotinib or gefitinib (LUX-Lung1): a preliminary report",
        "LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both",
        "Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial",
        "Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non\u2013small-cell lung cancer",
        "WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors",
        "Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC",
        "AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer",
        "Targeting drug resistance in EGFR with covalent inhibitors: a structure-based design approach",
        "Novel mutant-selective EGFR kinase inhibitors against EGFR T790M",
        "Discovery of selective irreversible inhibitors for EGFR-T790M",
        "Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imid azol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers",
        "Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy",
        "Postoperative chemotherapy use and outcomes from ADAURA: osimertinib as adjuvant therapy for resected EGFR-mutated NSCLC",
        "Acquired resistance to the mutant-selective EGFR inhibitor AZD9291 is associated with increased dependence on RAS signaling in preclinical models",
        "Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor",
        "Insights into the aberrant activity of mutant EGFR kinase domain and drug recognition",
        "CH7233163 Overcomes Osimertinib Resistant EGFR-Del19/T790M/C797S Mutation",
        "MarvinSketch and MarvinView: Molecule Applets for the World Wide Web",
        "pK a based protonation states and microspecies for protein\u2013ligand docking",
        "Involvement of Nrf2 and Keap1 in the activation of antioxidant responsive element (ARE) by chemopreventive agent peptides from soft-shelled turtle",
        "Routine microsecond molecular dynamics simulations with AMBER on GPUs. 1. Generalized born",
        "Structural insight into the recognition of S-adenosyl-L-homocysteine and sinefungin in SARS-CoV-2 Nsp16/Nsp10 RNA cap 2\u2032-O-Methyltransferase",
        "Butoxy Mansonone G inhibits STAT3 and Akt signaling pathways in non-small cell lung cancers: combined experimental and theoretical investigations",
        "The investigation of binary and ternary sulfobutylether-\u03b2-cyclodextrin inclusion complexes with asiaticoside in solution and in solid state",
        "Computational study on peptidomimetic inhibitors against SARS-CoV-2 main protease",
        "ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB",
        "Development and testing of a general amber force field",
        "Binding hotspot and activation mechanism of maltitol and lactitol toward the human sweet taste receptor",
        "Rosmarinic acid as a potent influenza neuraminidase inhibitor: in vitro and in silico study",
        "Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes",
        "Comparison of simple potential functions for simulating liquid water",
        "The effect of long-range electrostatic interactions in simulations of macromolecular crystals: a comparison of the Ewald and truncated list methods",
        "PTRAJ and CPPTRAJ: software for processing and analysis of molecular dynamics trajectory data",
        "ProDy: protein dynamics inferred from theory and experiments",
        "MMPBSA. py: an efficient program for end-state free energy calculations",
        "How does chirality determine the selective inhibition of histone deacetylase 6? A lesson from trichostatin a enantiomers based on molecular dynamics",
        "Subtype-selective mechanisms of negative allosteric modulators binding to group I metabotropic glutamate receptors",
        "What contributes to serotonin\u2013norepinephrine reuptake inhibitors' dual-targeting mechanism? The key role of transmembrane domain 6 in human serotonin and norepinephrine transporters revealed by molecular dynamics simulation",
        "Identification of vinyl sulfone derivatives as EGFR tyrosine kinase inhibitor: in vitro and in silico studies",
        "Structural and energetic basis for the molecular recognition of dual synthetic vs. natural inhibitors of EGFR/HER2",
        "Evaluation of the binding behavior of olmutinib (HM61713) with model transport protein: insights from spectroscopic and molecular docking studies",
        "Investigation on the protein-binding properties of icotinib by spectroscopic and molecular modeling method",
        "First-line single agent treatment with gefitinib in patients with advanced non\u2013small-cell lung cancer: a phase II study",
        "Long-term treatment with erlotinib for EGFR wild-type non-small cell lung cancer: a case report",
        "Osimertinib in untreated EGFR-mutated advanced non\u2013small-cell lung cancer",
        "Impact of clinical features of epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) patients on osimertinib efficacy",
        "Osimertinib in first line setting: preventive or delayed T790M occurrence?",
        "Why statistics matter: limited inter-rater agreement prevents using the psoriasis area and severity index as a unique determinant of therapeutic decision in psoriasis",
        "The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood",
        "User's guide to correlation coefficients",
        "Ten things you should know about protein kinases: IUPHAR R eview 14",
        "Insight into the therapeutic selectivity of the irreversible EGFR tyrosine kinase inhibitor osimertinib through enzyme kinetic studies",
        "Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations",
        "Exploring gatekeeper mutations in EGFR through computer simulations",
        "Successful treatment of a lung adenocarcinoma patient with a novel EGFR exon 20-ins mutation with afatinib: a case report",
        "Acquired resistance to the mutant-selective EGFR inhibitor AZD9291 is associated with increased dependence on RAS signaling in preclinical models",
        "Understanding kinase selectivity through energetic analysis of binding site waters",
        "Enhanced dimerization drives ligand-independent activity of mutant epidermal growth factor receptor in lung cancer",
        "Active and inactive protein kinases: structural basis for regulation",
        "Structural signature of the G719S-T790M double mutation in the EGFR kinase domain and its response to inhibitors",
        "Rational design of non-resistant targeted cancer therapies",
        "Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor",
        "FDA-approved small-molecule kinase inhibitors",
        "Dual blockade of EGFR tyrosine kinase using osimertinib and afatinib eradicates EGFRmutant Ba/F3 cells",
        "Osimertinib as first-line therapy in advanced NSCLC: a profile of its use",
        "Free-energy landscape, principal component analysis, and structural clustering to identify representative conformations from molecular dynamics simulations: the myoglobin case"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Khon Kaen",
            "@id": "60026046",
            "affilname": "Faculty of Medicine, Khon Kaen University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60026046",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60021944",
            "affilname": "Kasetsart University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60021944",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Thonburi",
            "@id": "60008786",
            "affilname": "King Mongkut's University of Technology Thonburi",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60008786",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Thailand Science Research and Innovation Fund Chulalongkorn University",
        "Chulalongkorn University",
        "Faculty of Medicine, Khon Kaen University",
        "King Mongkut's University of Technology Thonburi",
        "PCA"
    ]
}